Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350-Reference-Cited by-同舟云学术

Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350

Published:2008-09 Issue:17 Volume:18 Page:4853-4858
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Raboisson Pierre,de Kock Herman,Rosenquist Åsa,Nilsson Magnus,Salvador-Oden Lourdes,Lin Tse-I,Roue Natalie,Ivanov Vladimir,Wähling Horst,Wickström Kristina,Hamelink Elizabeth,Edlund Michael,Vrang Lotta,Vendeville Sandrine,Van de Vreken Wim,McGowan David,Tahri Abdellah,Hu Lili,Boutton Carlo,Lenz Oliver,Delouvroy Frederic,Pille Geert,Surleraux Dominique,Wigerinck Piet,Samuelsson Bertil,Simmen Kenneth

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference25 articles.

1. Hepatitis C Virus Infection

2. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection

3. Interferon-??-2b Plus Ribavirin

4. Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection

Cited by 136 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Macrocyclic-based strategy in drug design: From lab to the clinic;European Journal of Medicinal Chemistry;2024-11

2. The Structure-property Relationships of Clinically Approved Protease Inhibitors;Current Medicinal Chemistry;2024-04

3. Hepatitis C: The Story of a Long Journey through First, Second, and Third Generation NS3/4A Peptidomimetic Inhibitors. What Did We Learn?;Journal of Medicinal Chemistry;2024-01-05

4. Exploring the synthetic approaches and clinical prowess of established macrocyclic pharmaceuticals;European Journal of Medicinal Chemistry;2024-01

5. Synthetic approaches and application of clinically approved small-molecule drugs to treat hepatitis;European Journal of Medicinal Chemistry;2023-12